Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea.
10.3346/jkms.2016.31.10.1579
- Author:
Yoojoo LIM
1
;
Jeong Ok LEE
;
Soo Mee BANG
Author Information
1. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea. smbang7@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Myeloproliferative Neoplasm;
Incidence;
Prevalence;
Survival;
Korea
- MeSH:
Humans;
Hydroxyurea;
Incidence*;
Insurance, Health;
Korea*;
Phlebotomy;
Polycythemia Vera;
Prescriptions;
Prevalence*;
Primary Myelofibrosis;
Survival Rate;
Thrombocythemia, Essential
- From:Journal of Korean Medical Science
2016;31(10):1579-1585
- CountryRepublic of Korea
- Language:English
-
Abstract:
The nationwide statistical analysis of each disease of classical myeloproliferative neoplasm (MPN) in Korea has not been reported yet. To this end, we have analyzed incidence rates, survival rates and treatment pattern of polycythemia vera (PV), primary myelofibrosis (MF) and essential thrombocythemia (ET) using Korea National Cancer Incidence Database (KNCIDB) and Health Insurance Review and Assessment Service (HIRA) database. Between 2003 and 2011, a total of 4,342 new cases of MPN were reported to the KNCIDB. ET was the most common, followed by MF and PV. The crude incidence rates for PV, MF, and ET have increased during the period, reaching 0.40, 0.15, and 0.84 per 100,000, respectively. Five-year relative survival rate of all MPN patients was 89.3%, with lowest relative survival rate with MF (53.1%). The prevalence of each disease estimated from HIRA data also increased during the study period. Notably, ET was found to be most prevalent. The prescription rate of hydroxyurea and phlebotomy to PV, MF and ET patients remained constant over the period, and the prescription rate of hydroxyurea was higher in patients with age over 60 years. This is the first Korean nationwide statistics of MPN, using central registry data. This set of data can be utilized to compare the Korean MPN status to international data and guidelines.
